| abstract |
Microarray analysis, confirmed by RT-PCT, demonstrated that lung squamous cell carcinoma, colon/colorectal cancer, and breast carcinoma mRNA hybridizes specifically and preferentially to ADAM12L. Microarray analysis also demonstrated that RNA from malignant bladder, pancreas, and stomach tissue hybridizes specifically to ADAM12. ADAM12L is a transmembrane protein overexpressed on the surface of cancer cells compared to normal tissues and thus provides a therapeutic target for treating cancer. Modulators of ADAM12, highly expressed in cancerous as compared to normal tissues, are provided for the diagnosis and treatment of proliferative disorders such as cancer and psoriasis. The invention further provides methods of treating cancer with therapeutic agents directed toward ADAM12. |